Arsanis (ASNS) Now Covered by Analysts at Piper Jaffray Companies
Piper Jaffray Companies started coverage on shares of Arsanis (NASDAQ:ASNS) in a research report sent to investors on Monday morning, Marketbeat reports. The brokerage issued an overweight rating and a $23.00 price objective on the stock.
Arsanis (NASDAQ:ASNS) opened at $11.63 on Monday. Arsanis has a twelve month low of $10.40 and a twelve month high of $19.73.
In other news, major shareholder Polaris Venture Management Co. bought 500,000 shares of the firm’s stock in a transaction on Monday, November 20th. The stock was acquired at an average cost of $10.00 per share, with a total value of $5,000,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Tillman U. Gerngross bought 200,000 shares of the firm’s stock in a transaction on Monday, November 20th. The stock was purchased at an average cost of $10.00 per share, with a total value of $2,000,000.00. The disclosure for this purchase can be found here.
Arsanis Company Profile
Arsanis, Inc is a biopharmaceutical company. The Company is focused on the discovering and developing monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. The Company’s mAbs focus on specific pathogens and pathogenic processes. Its product pipeline includes ASN100, ASN200, ASN300, ASN400 and ASN500.
Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.